SCHEMBL44642

SCHEMBL44642

CCCCOC(=O)N1CC(F)CC1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA2 Q9HCG7 1/20 0.42
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.36
ECE1 P42892 1/20 0.36
ALDH1A1 P00352 1/20 0.36
ATM Q13315 2/20 0.34
HCAR2 Q8TDS4 1/20 0.34
RAB9A P51151 1/20 0.34
PEPD P12955 1/20 0.33
XPNPEP1 Q9NQW7 1/20 0.33
S1PR1 P21453 2/20 0.33
S1PR5 Q9H228 2/20 0.33
PPP5C P53041 1/20 0.33
BCHE P06276 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
KDM4E B2RXH2 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18576470 0.86 ATM (0.39) ATMRAB9APEPDXPNPEP1TSHR
SCHEMBL15719677 0.86 PEPD (0.47) GBA2LMNAPOLBSMN1; SMN2ECE1
SCHEMBL10084439 0.84 ATM (0.53) GBA2LMNAPOLBSMN1; SMN2L3MBTL1
SCHEMBL20558080 0.84 ATM (0.53) GBA2LMNAPOLBSMN1; SMN2L3MBTL1
SCHEMBL3663153 0.84 ATM (0.53) GBA2LMNAPOLBSMN1; SMN2L3MBTL1
SCHEMBL31728231 0.84 ATM (0.53) GBA2LMNAPOLBSMN1; SMN2L3MBTL1
SCHEMBL10084437 0.84 ATM (0.53) GBA2LMNAPOLBSMN1; SMN2L3MBTL1
SCHEMBL10292032 0.84 ATM (0.53) GBA2LMNAPOLBSMN1; SMN2L3MBTL1
SCHEMBL1585134 0.84 GBA2 (0.46) GBA2LMNAPOLBSMN1; SMN2L3MBTL1
SCHEMBL10085243 0.83 GBA2 (0.42) GBA2LMNAPOLBSMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4308095-A1 INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF Maze Therapeutics, Inc. (US) 2024-01-24 EP disclosed
US-20230365594-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. 2023-11-16 US disclosed
US-11661431-B2 Thienopyrrole compounds GILEAD SCIENCES, INC. (US) 2023-05-30 US disclosed
US-20220389034-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. 2022-12-08 US disclosed
WO-2022198196-A1 INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2022-09-22 WO disclosed
EP-3166939-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF Genentech, Inc. (US) 2017-05-17 EP disclosed
WO-2016007534-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2016-01-14 WO disclosed
WO-2011149993-A2 SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2011-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365594-A1 THIENOPYRROLE COMPOUNDS SSB, TPMT, LCP2 GBA2 1406/4885LMNA 1961/4885POLB 2922/4885
US-11661431-B2 Thienopyrrole compounds SSB, TPMT, LCP2 GBA2 1406/4885LMNA 1961/4885POLB 2922/4885
US-20220389034-A1 THIENOPYRROLE COMPOUNDS SSB, TPMT, LCP2 GBA2 1406/4885LMNA 1961/4885POLB 2922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.